Get the Stockscreener App
169.64
3.72%
-6.55
After Hours:
169.64
Charles River Laboratories International Inc stock is traded at $169.64, with a volume of 670.90K.
It is down -3.72% in the last 24 hours and up +11.80% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$176.19
Open:
$174.72
24h Volume:
670.90K
Relative Volume:
0.67
Market Cap:
$8.33B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
21.18
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-4.21%
1M Performance:
+11.80%
6M Performance:
+2.96%
1Y Performance:
-30.50%
1-Day Range:
$169.05
$176.15
1-Week Range:
$169.05
$180.44
52-Week Range:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
169.64 | 8.65B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Stock Analysis | Charles River Laboratories International OutlookA Mixed Picture for Investors - AInvest
Charles River explores crowdfunding partnership with BioTech Social - StreetInsider
Charles River explores crowdfunding option for incubator participants - Investing.com
Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership - Stock Titan
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo.co
Charles River Q2 Earnings Preview: What's in Store for the Stock? - Yahoo Finance
Sectors Driving Future Growth for Charles River Laboratories International Inc. StockOversold Bounce Stock Play Ideas Gain Attention - metal.it
Pharma Formulation Development Outsourcing Forecast Report - GlobeNewswire
How Charles River Laboratories International Inc. stock reacts to Fed policy changesValue Investing Picks With Stability Outlined - metal.it
What catalysts could drive Charles River Laboratories International Inc. stock higher in 2025Superior stock selection - jammulinksnews.com
Is Charles River Laboratories International Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - jammulinksnews.com
What are the technical indicators suggesting about Charles River Laboratories International Inc.Invest confidently with professional market insights - jammulinksnews.com
How strong is Charles River Laboratories International Inc. company’s balance sheetTriple-digit returns - jammulinksnews.com
What institutional investors are buying Charles River Laboratories International Inc. stockRapid wealth creation - jammulinksnews.com
What are Charles River Laboratories International Inc. company’s key revenue driversSky-high profits - jammulinksnews.com
Is it the right time to buy Charles River Laboratories International Inc. stockAchieve consistent profits with expert advice - jammulinksnews.com
Competitive Positioning of Charles River Laboratories International Inc.: Is It Leading or LaggingAI Powered Stock Call - metal.it
Is Charles River Laboratories International Inc. a Top Dividend Stock to Watch in 2025Low Risk High Reward Picks - metal.it
How does Charles River Laboratories International Inc. compare to its industry peersGrow your wealth steadily and securely - jammulinksnews.com
What analysts say about Charles River Laboratories International Inc. stockFree Real-Time Stock Data - PrintWeekIndia
What drives Charles River Laboratories International Inc. stock priceExplosive trading opportunities - PrintWeekIndia
Is Charles River Laboratories International Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia
Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-yield investments - Autocar Professional
Charles River Laboratories Surges 134.22% in Trading Volume, Ranks 365th in Daily Market - AInvest
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development - StreetInsider
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today | Markets | American Financial Group, Inc. - FinancialContent
Charles River Laboratories Surged 8.6% Intraday—Is This a Game-Changer for Biotech Innovation? - AInvest
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):